Rhodiola rosea is a short-acting root extract used as a fatigue and stress tonic. The clearest human signal is modest easing of stress-related tiredness and a small improvement in endurance and perceived effort, mainly with standardized extracts taken in the morning or before work. Evidence is mixed. Retail extracts often fail authenticity tests. Not a proven lifespan intervention. (Full Review)

Protocol

Common practitioner range

200–400 mg once daily

Standardized root extract, or 288–576 mg/day of SHR-5-type extract; 680 mg/day practical ceiling

Time of day

Morning or 30–60 min pre-training

Full daily amount before noon; split only if the total exceeds ~300 mg and the second amount lands before early afternoon

Competing schools

Daily under load, or pre-session

Daily low-dose for weeks under load, or 100–200 mg before hard sessions

Time to effect

Stress-related fatigue

1–12 weeks

Scores often move within 1 week and continue through 4–12 weeks

Endurance

60 minutes

Acute studies measure a change 60 minutes after one dose

Benefits

Medium: Reduced stress-related fatigue; Small gains in endurance and lower perceived effort; Mild-to-moderate depressive symptoms

Low: Lower self-reported anxiety under life stress; Faster recovery markers after hard training

Speculative: Longer life in worms and flies; Neuroprotection in laboratory models; Metabolic tone in laboratory models

Contraindications

Pregnancy and lactation

Bipolar disorder or prior mania/hypomania (milder elevated mood without full mania)

Children and adolescents

Uncontrolled autoimmune flare

People who cannot verify extract authenticity

Key Interactions

CYP2C9 substrates (warfarin, phenytoin, celecoxib)

CYP3A4 and P-gp substrates (some statins, midazolam, digoxin)

SSRIs and other serotonergic drugs (sertraline, fluoxetine, tramadol, St. John’s wort)

MAO inhibitors (phenelzine, tranylcypromine; caution approaching contraindication)

Stimulant over-the-counter products (pseudoephedrine, high-dose caffeine)

Other adaptogens and calming combinations (ashwagandha, theanine, magnesium)

Antihypertensives and hypoglycemic drugs (lisinopril, metformin)

Risk & Side Effects

Medium: Mild stimulatory and autonomic adverse events; Authentic-product failure and species substitution; Modest CYP2C9 inhibition

Low: Possible additive serotonergic effects with antidepressants

Speculative: Mania in bipolar-spectrum illness; Autoimmune flare; Low blood glucose

Monitoring

Marker	Target	Why
Morning serum or salivary cortisol	Track change from own baseline; clear awakening rise that settles by afternoon	Can flatten an exaggerated cortisol awakening response
Fasting plasma glucose	70–85 mg/dL	Animal and precautionary notes on glucose lowering
Resting blood pressure	<120/80 mmHg	Occasional pressure-lowering and stimulatory pulse reports
INR (if on warfarin)	Prescriber’s target, often 2.0–3.0	Documents the 21% CYP2C9 shift
Body weight / waist	Individual baseline	Indirect check if appetite or training volume changes

Cadence: 1 week (sleep, restlessness, blood pressure); 4 weeks (fatigue or training logs, repeat glucose and pressure); every 3–6 months if use continues; drug-level recheck 3–7 days after start or stop on CYP2C9 substrates

Qualitative Assessment

Sleep-onset latency and night wakings
Afternoon energy and perceived exertion on a familiar session
Irritability, pressured speech (talking faster than usual and hard to interrupt), or decreased need for sleep (mood-switch watch)
Dry mouth, headache, or restlessness in the first week
Training log: same-route time, repeats to fatigue, or session rating of perceived exertion

Rhodiola rosea for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment